The Experts below are selected from a list of 153 Experts worldwide ranked by ideXlab platform
Frenil Munim - One of the best experts on this subject based on the ideXlab platform.
-
Nonfermenting Gram-negative Bacilli other than Pseudomonas aeruginosa and Acinetobacter Spp. Causing Respiratory Tract Infections in a Tertiary Care Center.
Journal of global infectious diseases, 2013Co-Authors: Kisumu Chawla, Shashidhar Vishwanath, Frenil MunimAbstract:Background: Nonfermenting gram-negative Bacilli have emerged as important healthcare-associated pathogens. It is important to correctly identify all clinically significant nonfermenting gram-negative Bacilli considering the intrinsic multidrug resistance exhibited by these bacteria. Materials and Methods: A retrospective study was undertaken to identify the various nonfermenting gram-negative Bacilli other than Pseudomonas aeruginosa and Acinetobacter spp. isolated from respiratory samples (n = 9363), to understand their clinical relevance and to analyze their antibiotic susceptibility pattern. Results: Nonfermenting gram-negative Bacilli were isolated from 830 (16.4%) samples showing significant growth. Thirty-three (4%) isolates constituted nonfermenting gram-negative Bacilli other than P. aeruginosa and Acinetobacter spp. Stenotrophomonas maltophilia (15, 45.5%) was the most common isolate followed by Burkholderia cepacia (4, 12.1%), Sphingomonas paucimobilis (3, 9.1%), and Achromobacter xylosoxidans (3, 9.1%). On the basis of clinicomicrobiological correlation, pathogenicity was observed in 69.7% (n = 23) isolates. Timely and correct treatment resulted in clinical improvement in 87.9% cases. Conclusion: Any nonfermenting gram-negative Bacilli isolated from respiratory tract infection should not be ignored as mere contaminant, but correlated clinically for its pathogenic potential and identified using standard methods so as to institute appropriate and timely antibiotic coverage.
William R Jacobs - One of the best experts on this subject based on the ideXlab platform.
-
pyrazinoic acid and its n propyl ester inhibit fatty acid synthase type i in replicating tubercle Bacilli
Antimicrobial Agents and Chemotherapy, 2007Co-Authors: Oren Zimhony, John T Welch, Masayoshi Arai, Catherine Vilcheze, William R JacobsAbstract:The activity of different analogs of pyrazinamide on Mycobacterium tuberculosis fatty acid synthase type I (FASI) in replicating Bacilli was studied. Palmitic acid biosynthesis was diminished by 96% in Bacilli treated with n-propyl pyrazinoate, 94% in Bacilli treated with 5-chloro-pyrazinamide, and 97% in Bacilli treated with pyrazinoic acid, the pharmacologically active agent of pyrazinamide. We conclude that the minimal structure of pyrazine ring with an acyl group is sufficient for FASI inhibition and antimycobacterial activity.
Pan Liuying - One of the best experts on this subject based on the ideXlab platform.
-
Characterization of antibiotic resistance of nosocomial Bacilli infection in cancer patients.
Journal of Tropical Medicine, 2009Co-Authors: Liao Zhihong, Liu Zhihua, Xu Qiuhong, Ma Limei, Pan LiuyingAbstract:Objective To investigate the antibiotic resistance of Bacilli isolated from cancer patients.Method 198 cases nosocomial infection of tumor patients were analyzed.The isolated Bacilli and their antibiotic resistance were analyzed.Result The total pathogen positive rate was 75.4%,in which 60.8% were Gram-negative Bacilli,28.9% were Gram-positive Bacilli and 10.3% were fungus.The most common antibiotic resistant pathogens were Escherichia coli,Klebsiella pneumoniae,Staphylococcus aureus and Pseudomonas aeurginosa.Conclusion Gram-negative Bacilli were the major pathogens causing nosocomial infection in tumor patients.The antibiotic resistance was increasing obviously.Antibiotics should be used properly to decrease the drug resistance and to prevent the infection in tumor patients.
Kisumu Chawla - One of the best experts on this subject based on the ideXlab platform.
-
Nonfermenting Gram-negative Bacilli other than Pseudomonas aeruginosa and Acinetobacter Spp. Causing Respiratory Tract Infections in a Tertiary Care Center.
Journal of global infectious diseases, 2013Co-Authors: Kisumu Chawla, Shashidhar Vishwanath, Frenil MunimAbstract:Background: Nonfermenting gram-negative Bacilli have emerged as important healthcare-associated pathogens. It is important to correctly identify all clinically significant nonfermenting gram-negative Bacilli considering the intrinsic multidrug resistance exhibited by these bacteria. Materials and Methods: A retrospective study was undertaken to identify the various nonfermenting gram-negative Bacilli other than Pseudomonas aeruginosa and Acinetobacter spp. isolated from respiratory samples (n = 9363), to understand their clinical relevance and to analyze their antibiotic susceptibility pattern. Results: Nonfermenting gram-negative Bacilli were isolated from 830 (16.4%) samples showing significant growth. Thirty-three (4%) isolates constituted nonfermenting gram-negative Bacilli other than P. aeruginosa and Acinetobacter spp. Stenotrophomonas maltophilia (15, 45.5%) was the most common isolate followed by Burkholderia cepacia (4, 12.1%), Sphingomonas paucimobilis (3, 9.1%), and Achromobacter xylosoxidans (3, 9.1%). On the basis of clinicomicrobiological correlation, pathogenicity was observed in 69.7% (n = 23) isolates. Timely and correct treatment resulted in clinical improvement in 87.9% cases. Conclusion: Any nonfermenting gram-negative Bacilli isolated from respiratory tract infection should not be ignored as mere contaminant, but correlated clinically for its pathogenic potential and identified using standard methods so as to institute appropriate and timely antibiotic coverage.
Louise M Pitt - One of the best experts on this subject based on the ideXlab platform.
-
efficacies of bcg and vole bacillus mycobacterium microti vaccines in preventing clinically apparent pulmonary tuberculosis in rabbits a preliminary report
Vaccine, 2000Co-Authors: Arthur M Dannenberg, William R Bishai, Nikki Parrish, Rafael Ruiz, Walter Johnson, Bernard C Zook, James W Boles, Louise M PittAbstract:Tuberculosis (TB) kills more people in the world today than any other infectious disease, and the number of drug-resistant Mycobacterium tuberculosis isolates is increasing. Vaccines, better than most of the currently available strains of bacille Calmette–Guerin (BCG), are urgently needed to control this disease. TB in rabbits resembles human TB more closely than TB in any other common laboratory animal and a most pertinent method of assessing vaccine efficacy is Lurie's tubercle count method in this species. Vaccinated and control rabbits were infected by aerosol with virulent human-type tubercle Bacilli (H37Rv). At necropsy 5 weeks thereafter, the grossly visible primary tubercles in the entire lung were counted. A decrease in the number of such tubercles is a quantitative measure of vaccine efficacy: An effective vaccine prevents microscopic tubercles from growing to grossly visible (clinically apparent) size. The Pasteur substrain of BCG and two substrains of Mycobacterium microti (the vole bacillus) reduced the number of visible primary tubercles an average of 75%, whereas three other substrains of BCG and three other substrains of vole Bacilli only reduced the number an average of 40%. These initial studies indicate that Lurie's tubercle-count method in rabbits is a precise way to choose the best available tuberculosis vaccines.
